Inhaled cyclosporine: a safe and effective aerosol therapy for chronic graft versus host disease involving lung  by Anderson, P.M. et al.
can be achieved. Attempts to accomplish this must consider drug
interactions with itraconazole and acetaminophen, both of which
increase Bu level by competing for glutathione reductase depen-
dent metabolism, or dilantin and rifampicin, which decrease Bu
level due to metabolic pathway activation. We developed a limited
sampling strategy that simpliﬁes Bu PK when the iv drug is used.
We have begun studies to determine the ability of test dose PK to
predict later Bu levels. Pts are given the ﬁrst of 16 2-hr infusions of
ivBu “test dose” 48 hr prior to the beginning of the remaining 15
Q6h doses adjusted to achieve a target AUC on the basis of 1st dose
PK. PK study is performed using a 5-sample limited sampling
strategy and a single compartment, ﬁrst order elimination model in
WinNonlin. Pts receive lorazepam for seizure prophylaxis to avoid
any dilantin effect. 13 Pts received this Bu-based HSCT prepara-
tive regimen between April and June 2003, 5 required no dose
adjustment for dose 2, 5 required an increase and 3 required a
decrease. Despite adjustment we found greater than 10% variation
from predicted AUC for dose 2 in 5 Pts. The largest (30% higher
than predicted) occurred in a Pt who received voriconazole be-
tween dose 1 and dose 2. The second largest (23% lower that
predicted) occurred in a Pt who was taking an acetaminophen prior
to dose 1. The 3rd and 4th highest (21% and 14% higher than
predicted) occurred in Pts with a rise in serum bilirubin level
between doses. Thus 8/9 Pts without a presumptive cause for
instability in drug metabolism, including previously undocumented
concomitant voriconazole, had dose 2 AUC within 10% of pre-
dicted using dose 1 PKDT. Dosing precision with ivBu is achiev-
able, but precautions to assure absence of drug interaction or
changing hepatic function are necessary. Dosing precision with
ivBu will improve safety and effectiveness of HSCT using Bu-
based preparative regimens and greatly facilitate research into
modiﬁed preparative regimens for allogeneic HSCT.
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SUCCESSFUL TREATMENT OF HEPATIC VENO-OCCLUSIVE DIS-
EASE(VOD) AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION
BY EARLY ADMINISTRATION OF A SHORT COURSE OF METHYLPRED-
NISOLONE
AlBeihany, A.M., AlOmar, H.A., Sahovic, E., Chaudhri, N.A., AlMo-
hareb, F.I., AlShanqeeti, A., AlSharif, F., AlZahrani, H., Seth, P.,
AlQurashi, F., Zaidi, S., Morshed, M., AlHijazi, A., Gyger, M., Aljurf,
M.D. Oncology Dept, King Faisal Specialist Hospital& Research Center,
Riyadh, Saudi Arabia.
Hepatic Veno-Occlusive Disease (VOD) is a well-recognized life
threatening complication of hemopoietic stem cell transplantation.
Cytokine release from tissue injury resulting from high doses of
chemo/radiotherapy plays a major role in pathogenesis of VOD.
We postulate that corticosteroids might ameliorate the severity of
disease and improve the outcome. Between January 1997 and
December 2002, 410 consecutive adult patients received allogeneic
stem cell transplant at our institution. Using Seattle’s criteria, 49
patients were diagnosed to have VOD (11%). Treatment consisted
of methylprednisolone (MP) 0.5mg/kg i.v. q.12.h for seven days,
and standard supportive therapy of ﬂuid/salt restriction and diuret-
ics. Median age was 29 years (15.4-55.7). Twenty-four patients
were male and 25 were female. Primary diagnoses were AML (13),
ALL (12), CML (17), MDS (6), NHL (1). Bone marrow was the
source of stem cells in 43 (87.8%), and peripheral blood in 6
(12.2%) patients. All donors were HLA-matched siblings except
for a case of one antigen mismatch. Thirty-six (73.5%) patients
received conditioning with Bu/Cy and 13 (26.5%) TBI containing
regimen. GVHD prophylaxis was standard CSA with short course
of methotrexate. All patients received Fluconazole prophylaxis and
G-CSF was used in 31 (63%) patients. One patient was positive for
Hepatitis B surface antigen and one had hepatitis C virus antibod-
ies. Median bilirubin was 169 m m/L (38-1169). Weight gain was
present in 47 (90%) patients and right upper quadrant tenderness
in 43 (87%) patients. Thirty-two (65%) of the patients had other
organ failure(s) including multi-organ failure (MOF) in 15, renal in
9, respiratory in 6, cardiac failure, and CNS toxicity in 1 patient.
Response was deﬁned using Bearman’s criteria (Blood 1997; 89:
1501-1506) as reduction by 50% of serum bilirubin within 10 days
of initiation of high dose MP. Results: Twenty (40%) patients
responded to treatment. By day100, 17 (35%) patients were alive
and without evidence of VOD, all were among responders to
therapy. There were no serious adverse effects of treatment.
Causes of death were: VOD in 11, relapse in 10, MOF in 7,
pneumonitis in 1, bleeding in 1, infection in 1, and one sudden
death at home. We conclude that MP is safe and effective treat-
ment of VOD. Our response and survival data compare favorably
with other available reported alternative therapies for VOD; how-




RISK ASSESSMENT AND OUTCOME OF CHRONIC GRAFT-VERSUS-HOST
DISEASE AFTER ALLOGENEIC PERIPHERAL BLOOD PROGENITOR CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS
Diaz, M.A.1, Gonzalez Vicent, M.1, Gonzalez Valentin, M.E.2, Ver-
deguer, A.3, de la Rubia, J.3, Bargay, J.4, de Arriba, F.5, Diez, J.L.6,
Caballero, D.7, Madero, L.1, Brunet, S.8 1. Hospital Infantil “Nin˜o
Jesus,” Madrid, Madrid, Spain; 2. Hospital “Carlos Haya,” Malaga,
Malaga, Spain; 3. Hospital “La Fe,” Valencia, Valencia, Spain; 4.
Hospital Son Dureta, Mallorca, Mallorca, Spain; 5. Hospital Gral,
Murcia, Murcia, Spain; 6. Hospital “Gregorio Maran˜on,” Madrid,
Madrid, Spain; 7. Hospital Clinico Universitario, Salamanca,
Salamanca, Spain; 8. Hospital San Pau, Barcelona, Barcelona, Spain.
We evaluated the incidence, risk factors for cGvHD and clinical
outcome in 80 pediatric patients (36 male and 44 female) (median
age 13 years; range 1 to 18) who underwent allogeneic PBPC
transplantation. All patients were grafted from an HLA-identical
sibling after myeloablative conditioning (TBI-based 52; non-TBI
28). GvHD prophylaxis used were CsA short methotrexate in 52
and CsA predinosone in 28. The median number of CD34 cells
infused was 5.8 x 106/Kg (range; 1.4-32.8). The median follow-up
was 24 months (range; 3-94). Twenty-eight patients had cGvHD.
The cumulative incidence of cGvHD at 24 months was 54.210%.
Factors that were found signiﬁcant on univariate analysis were
diagnosis (p  0.03) and GvHD prophylaxis used (p  0.04). A
trend to higher risk of cGvHD was found with higher numbers of
CD34 and CD3 cells infused. On multivariate analysis, only
the GvHD prophylaxis used other than CsA plus short MTX was
associated with a signiﬁcant risk of cGvHD (HR 3.94; 95% CI:
1.41-10.91, p  0.009). The cumulative incidence of cGvHD for
patients receiving MTX was 40.912% whereas for patients who
did not received MTX was 76.518% (HR 2.39; 95% CI: 1.05-
7.49; p  0.03).
The probability of relapse was 366% for all patients, being of
12.58% for patients with cGvHD and 47.98% for patients
without cGvHD. There was no difference in the probability of
TRM between patients with or witout cGvHD (307% vs
146%; p  0.1). The probabilty of DFS was better for patients
with cGvHD (69.910% vs 37.97%; HR 3.59, 95% CI: 1.47-
5.56; p 0.001). In conclusion, our data suggest that the incidence
of cGvHD after allogeneic PBPC transplantation in children is
higher than reported using bone marrow and that the usually
considered risk factors for cGvHD in bone marrow were not found
associated with an increased risk of cGvHD being the GvHD
prophylaxis used the most relevant predictor of cGvHD. Patients
with cGvHD had a lower risk of relapse and a better survival.
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INHALED CYCLOSPORINE: A SAFE AND EFFECTIVE AEROSOL THERAPY
FOR CHRONIC GRAFT VERSUS HOST DISEASE INVOLVING LUNG
Anderson, P.M., Rodriguez, V., Erlandson, L., Heying, J., Brenna, J.,
Wylam, M.E. Mayo Clinic, Rochester, MN.
Bronchiolitis obliterans organizing pneumonia (BOOP) and
bronchiolitis obliterans (BO) are restrictive, inﬂammatory pro-
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cesses that can occur after hematopoietic stem cell transplantation.
In the allogeneic setting, pulmonary cytolytic thrombi and BOmay
be considered as lung components of acute and chronic graft versus
host disease (GVHD), respectively. Chronic GVHD with pulmo-
nary compromise is associated with high mortality. We report
results in a 6 year-old girl s/p haploidentical peripheral blood stem
cell transplant for biphenotypic acute leukemia. Initial post-trans-
plant course was complicated by aGVHD involving skin and gut.
She also had adenovirus successfully treated with cidofovir (1
mg/kg TIW). She subsequently developed cGVHD of the skin, gut
and lungs.
Pulmonary function deteriorated despite multiple, sequential ag-
gressive immune suppressive regimens including cyclosporine 
prednisone, tacrolimus  mycophenolate  prednisone, and in-
ﬂiximab  dacluzimab  prednisone. cGVHD of the skin and gut
resolved. Clinically, patient had chronic cough and exertional dys-
pnea. Chest CT showed patchy, interstitial pulmonary inﬁltrates.
Bronchoalveolar lavages excluded an infectious etiology. Pulmo-
nary function tests showed increasingly restrictive lung function
(see table below).
Inhaled cyclosporine was based on prior aerosol cyclosporine use
in lung transplantation for prevention and treatment of lung re-
jection (see Burkart GJ et al. Pharm Res 2003;20:252-6 ; Iacono AT
et al. Am J Resp Crit Care Med 1997;155:1690-1698; and Iacono
AT et al. Am J Resp Crit Care Med 1996;153:1451-1455). We
hypothesized that because aerosol cyclosporine can achieve higher
concentrations in the airways with prolonged pulmonary retention
compared to systemic immune suppression, it would be more
effective for cGVHD involving lung. Our goal was sustained pul-
monary improvement with less systemic toxicity.
Inhaled cyclosporine was slowly escalated to 75 mg as an aerosol
qd x 7 days, then tapered to 75 mg 3 times/week for 6 months.
Aerosol lidocaine was used as a pre-medication to prevent airway
irritation. Our patient had near normalization of her pulmonary
function tests after 1 month of aerosol cyclosporine. Treatment
was non-toxic and well tolerated as an outpatient. She continues in
excellent health and has a normal performance status. Thus, in this
patient, inhaled cyclosporine seemed to be a safe and effective
aerosol therapy for cGVHD of the lungs.
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DIFFERENTIAL GENE EXPRESSION PROFILES OF THE CD4CD25 T
SUPPRESSOR (TS) CELL POPULATION IN HUMAN CORD BLOOD AND
ADULT PERIPHERAL BLOOD VS MURINE SPLEEN CELLS
Chang, C.-C., Oberﬁeld, N., Satwani, P., van de Ven, C., Simpson,
L.L., Cairo, M.S. Children’s Hospital of New York-Presbyterian, Co-
lumbia University.
The incidence and severity of acute and chronic GvHD follow-
ing UCB transplant (UCBT) is signiﬁcantly less compared to that
of unrelated adult donor allogeneic stem cell transplant (Cairo et
al, Blood 90:4665, 1997). T suppressor (Ts) cells of the
CD4CD25 subset play a pivotal role in the maintenance of
immune unresponsiveness to allogeneic antigens in GvHD in a
rodent model (Taylor et al, Blood 99:3493, 2002 and Edinger et al.,
Nat Med 9:1144, 2003). We have previously demonstrated an
increase in CD4CD25 cells in CB vs. APB following secondary
alloantigen stimulation (Liu et al, Proc AACR 43:751, 3727a,
2002). In this study, we sought to determine if a group of genes
predominantly expressed in murine CD4CD25 Ts cells might
be used to evaluate the regulatory role of human Ts. CD4 T cells
of both CD25 and CD25- subsets were puriﬁed to 95% homo-
geneity from 4 APB and CB samples. Expression of various Ts
speciﬁc genes was determined by a dilution based semi-quantitative
RT-PCR analysis using CD25 and GAPDH as the internal posi-
tive and negative controls, respectively. Here we report that among
seventeen genes preferentially expressed in murine naive
CD4CD25 T cell subsets but not in activated CD4 T cells,
only eight of them exhibited similar predominant expression in
both human CB and APB Ts cells, including GITR, Foxp3,
CTLA-4, ECM-1, Irf4, Rarg, Rgs1, and Tnfrsf-1B. Expression of
some negative signaling molecules such as SOCS2 (suppressor of
cytokine signaling 2) and the inhibitory receptor PD-1, thought to
mediate the maintenance of the anergic state of Ts, failed to be
ampliﬁed from both CB and APB Ts cells, suggesting that human
Ts cells may require different mechanisms compared to murine Ts
cells to suppress immune responses. Our result identiﬁes a class of
molecules functionally indispensable for mediating inhibitory ac-
tivity of Ts in both humans and rodents. Future studies will
determine their physiological relevance in the context of Ts me-
diated suppression.
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THE ADDITION OF INTERLEUKIN (IL) -18 TO ANTI-CD3, IL-2 AND
IL-12 FOR EXPANSION AND ACTIVATION OF UMBILICAL CORD BLOOD
(UCB) CYTOTOXIC T-LYMPHOCYTES
Satwani, P., Ayello, J., van de Ven, C., Simpson, L., Cairo, M.S.
Children’s Hospital of New York-Presbyterian, Columbia University,
New York, NY.
A limitation of UCB as a source for adoptive cellular immunity
(ACI) is the limited number of immunoeffector T cell subsets
and/or UCB immaturity. We have previously demonstrated the ex
vivo expansion, maturation, and activation of fresh UCB derived T
lymphocytes with anti-CD3, IL-2, IL-12 and IL-7 (AB/CY) (Rob-
inson/Cairo et al, Exp Hem 30:245, 2001). IL-18 has been shown
to enhance T cell cytolytic activity and provide antitumor immu-
nity (Osaki et al, J Immunol 1998, 160: 1742), in addition to
working synergistically with IL-2 in NK cell proliferation (Son YI
et al, J Immunother, 2003, 26:234). We have shown that IL-18 acts
synergistically with IL-12 to induce NK and LAK cellular cyto-
toxicity in UCB (Cairo et al. J Pediatr Hematol/Oncol 2003;
25(4):8, p. S2.). For this study, we compared the expansion, mat-
uration, activation, and cell survival of UCB in IL-18 with the
AB/CY combination without IL-7. UCB MNCs were isolated by
Ficoll density centrifugation and incubated overnight @ 37°C, 5%
CO2 in serum free (SF) AIM-V media. The nonadherent MNC
fraction was cultured in SF AIM-V media alone and with IL-2 (5
ng/ml), IL-12 (10 ng/ml), anti-CD3 (50 ng/ml) and IL-18 (10
ng/ml) for 48 hours @ 5% CO2, 37°C. Expression of T cell
receptors was analyzed by ﬂow cytometry using CD3, CD45RO,
CD8, CD4, CD25, CD16, and CD56 monoclonal antibodies.
Apoptosis markers were determined by measuring Annexin V and
PI by ﬂow cytometry. Expression of lymphocyte subsets of CD8/
25 , CD4/25 and CD16/56 was signiﬁcantly increased in
the AB/CY with IL-18 compared to media alone (CD8/25:
58.416.4 vs 28.813.9%, p  0.05; CD4/25: 61.4  4.4 vs
2.9  0.9, p  0.001; CD16/56: 57.913.0 vs 24.07.1%, p 
0.05, respectively). There was no signiﬁcant increase in the CD3/
45RO activation when compared to media alone. To determine if
the increases were due in part to increased cell survival, AB/CY
with IL-18 expanded cultures demonstrated no signiﬁcant differ-
ence in apoptotic markers compared to media alone. In comparison
to historical data, there was no signiﬁcant difference in AB/CY
with IL-7 vs. AB/CY cocktail with IL-18. These data suggests that
CD8/25, CD4/25 and CD16/56 subsets can be ex vivo
expanded with AB/CY with IL-18 for possible use in ACI for DLI
after UCBT. In vitro functional and in vivo xenotransplant studies
are underway to further examine the cytolytic activity of these
activated UCB cell subsets.
Table. Pulmonary Function Tests: Before vs After Aerosol
Cyclosporine
Dates VC FVC FEV1 FEF 25–75
9/26/02 57% 56% 57% 38%
12/2/02 49% 48% 48% 20%
1/7/03 68% 63% 61% 26%
1/14/03 84% 84% 62% 30%
2/17/03 93% 92% 92% 59%
5/20/03 93% 94% 88% 46%
Values: % predicted; 1/10/03—began aerosol cyclosporine.
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